H.C. Wainwright adjusted the firm’s price target on Oncternal Therapeutics to $30 from $2 and keeps a Buy rating on the shares following the 1-for-20 reverse stock split that took effect earlier this month.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ONCT:
- Oncternal enrolls patients into third dosing cohort of Phase 1/2 trial
- Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
- Oncternal Therapeutics trading halted, news pending
- Oncternal Therapeutics Announces Reverse Stock Split
- Oncternal Therapeutics to effect 1-for-20 reverse stock split